About Arialys
Arialys is a company based in La Jolla (United States) founded in 2021. Arialys has raised $72.8 million across 2 funding rounds from investors including ARE, Avalon Bio Ventures and Catalys Pacific. Arialys offers products and services including ART5803. Arialys operates in a competitive market with competitors including George Institute, The Fertility Partners, HD, Novus Diagnostics and Genertec Universal Medical Group, among others.
- Headquarter La Jolla, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$72.8 M (USD)
in 2 rounds
-
Latest Funding Round
$14.8 M (USD), Seed
Jun 13, 2025
-
Investors
ARE
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Arialys
Arialys offers a comprehensive portfolio of products and services, including ART5803.
Antibody that blocks autoantibodies to treat anti-NMDA receptor encephalitis.
Funding Insights of Arialys
Arialys has successfully raised a total of $72.8M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $14.8 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arialys
Arialys has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Avalon Bio Ventures and Catalys Pacific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital firm backed by Johnson & Johnson
|
Locked | Locked | Locked | |
|
Invests in biotech companies via global networks and partnerships for disease treatments.
|
Locked | Locked | Locked |
Investor details for Arialys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arialys
Investment portfolio details for Arialys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arialys
Detailed financials for Arialys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arialys Comparisons
Peer comparison for Arialys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arialys
Arialys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as George Institute, The Fertility Partners, HD, Novus Diagnostics and Genertec Universal Medical Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical research is conducted by the institute in health fields.
|
|
| Locked | Locked | Locked |
Business consulting services for fertility practices are provided.
|
|
| Locked | Locked | Locked |
Medical information services are provided in the healthcare sector.
|
|
| Locked | Locked | Locked |
Provider of diagnostic information services for clinicians
|
|
| Locked | Locked | Locked |
Provider of medical information solutions
|
Detailed competitors of Arialys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arialys
Complete news archive for Arialys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arialys
Arialys was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Arialys is headquartered in La Jolla, United States. It is registered at La Jolla, California, United States.
Peter Flynn is the current CEO of Arialys.
Arialys is a funded company, having raised a total of $72.8M across 2 funding rounds to date.
Arialys was established in 2021 in La Jolla, United States, as a private biotech company. Focus is placed on the development of precision medicines targeting autoimmune neuropsychiatric diseases. Scientific advancements in this sector are investigated to support therapeutic interventions for individuals impacted by these conditions. Operations center on research and innovation within the biotechnology field.
Arialys's top competitors include George Institute, The Fertility Partners and HD.
Arialys offers ART5803.
Arialys has 5 investors. Key investors include ARE, Avalon Bio Ventures, Catalys Pacific, Turmeric Acquisition Corp, and Johnson & Johnson Innovation – JJDC.